期刊文献+

肝门部胆管癌的外科治疗 被引量:7

Surgical treatment of hilar cholangiocarcinoma
原文传递
导出
摘要 目的探讨肝门部胆管癌的临床特征、治疗方法对远期生存率的影响。方法对1995--2005年收治的98例肝门部胆管癌的l临床特点、诊断及随访结果进行回顾性分析,并将手术方式和治疗效果进行对比研究。根据数据类型分别进行χ2检验、t检验,生存率计算采用Kaplan-Meier法,并作log-rank检验。结果83例施行了外科手术,15例施行保守治疗。83例中行根治性切除术者33例,姑息性切除术者16例,内或外引流术者34例。肝门部胆管癌切除者1、3、5年生存率分别为79%、42%、17%,其中根治性切除1、3、5年生存率分别为88%、54%、24%;姑息性切除1、3年生存率分别为55%、9%,无5年存活者。根治性切除、姑息性切除生存率差异有统计学意义(10g-ranktest,P〈0.001)。结论根治性切除是提高肝门部胆管癌远期生存率及改善生活质量的有效手段,早期诊断和治疗是提高远期疗效的关键。 Objective To investigate the clinical features and the prognosis after surgical treatment for hilar cholangiocarcinoma (HCC). Methods The surgical therapy and follow-up result were retrospectively analyzed on 98 cases of hilar cholangiocarcinoma admitted into our hospital from January 1995 to January 2005. Differences between groups were evaluated using Chi-square analysis or Student t-test according to the data type. Survival rate was calculated with Kaplan-Meier method, and using the log-rank test. Results Among 98 patients, 83 patients underwent surgical treatment (radical resection in 33, palliative resection in 16, and nonresectional internal or external bile duct drainage in 34), 15 patients underwent conservative therapy. The 1-, 3-, 5-year survival rates were 79%, 42%, and 17% in the resection group and 88%, 54%, and 24% in the radical resection group, respectively. The 1-, 3-year survival rates were 55%, and 9% in palliative resection group, respectively, and none of the patient survived for over 5 years. There were significant differences in the survival rate among the radical resection group and the palliative resection group (log-rank test, P 〈 0. 001 ). Conclusions Radical resection improves the prognosis of hilar cholangiocarcinoma.
出处 《中华普通外科杂志》 CSCD 北大核心 2012年第12期966-969,共4页 Chinese Journal of General Surgery
基金 卫生部科学研究基金(WKJ2008-2-013) 河南省重点科技攻关(082102310086)
关键词 胆管肿瘤 胆道外科手术 预后 Common bile duct neoplasms Biliary tract surgical procedures Prognosis
  • 相关文献

参考文献6

二级参考文献17

共引文献75

同被引文献53

  • 1曹守强,邹小明,李福军,李晓林,张天华,秦华东,张建国.P57蛋白在胃癌中的表达及其临床意义[J].中华胃肠外科杂志,2004,7(4):300-300. 被引量:1
  • 2黄志强.肝门部胆管癌外科治疗——效果有待提高[J].临床外科杂志,2006,14(2):65-66. 被引量:42
  • 3Saxena A, Chua TC, Chu FC, et al. Improved outcomes afteraggressive surgical resection of hilar cholangiocarcinoma : acritical analysis of recurrence and survival [ J]. Am J Surg,2011,202(3):310 -320.
  • 4Edel EK, Bertrand BJ. The hallmarks of CDKN1C ( P57kip2 ) in cancer[ J]. Biochim Biophys Acta, 2011,1816( 1 ) :50-56.
  • 5Charbel H, AI-Kawas FH. Cholangiocarcinoma treatment [ J ]. Curr Gastroenterol Rep, 2012,14(6) :528-533.
  • 6Guo H, Tian T, Nan K, et al. p57 : a multifunctional protein in cancer[ J]. Int J Oncol, 2010,36 (6) : 1321-1329.
  • 7Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond [ J ]. Dev Cell, 2008,14 ( 2 ) : 159-169.
  • 8Vang R, Gupta M, Wu LS, et al. Diagnostic reproducibility of hy- datldiform moles : ancillary techniques (g57 immunobistochemistry and molecular genotyping ) improve morphologic diagnosis [ J ]. Am J Surg Pathol, 2012,36(3 ) :443453.
  • 9Shin JY, Kim HS, Lee KS, et al. Mutation and expression of the p27KIP1 and P57kip2 genes in human gastric cancer[ J]. Exp Mol Med, 2000,32(2) :79-83.
  • 10Dumitrascu T, Chirita D, Ionescu M, et al. Resection for hilar cholangiocarcinoma : analysis of prognostic factors and the impact of systemic inflammation on long-term outcome[J]. J Gastrointest Surg, 2013,17(5) :913-924.

引证文献7

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部